BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Has Average Price Target of $126.00 According to Brokerages

by · The Markets Daily

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX – Get Free Report) have received an average rating of “Moderate Buy” from the nineteen analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $126.00.

Several analysts have issued reports on BNTX shares. UBS Group reaffirmed a “buy” rating on shares of BioNTech in a research report on Wednesday, September 16th. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Canaccord Genuity Group dropped their target price on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a report on Monday, August 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research note on Friday. Finally, Citigroup reduced their price target on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, August 5th.

Read Our Latest Report on BioNTech

Insider Activity at BioNTech

In related news, CEO Ugur Sahin sold 17,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $97.46, for a total value of $1,656,820.00. Following the transaction, the chief executive officer owned 197,209 shares in the company, valued at approximately $19,219,989.14. This represents a 7.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 627,000 shares of company stock worth $61,967,005. Insiders own 19.20% of the company’s stock.

Institutional Investors Weigh In On BioNTech

A number of institutional investors have recently made changes to their positions in BNTX. Integrated Wealth Concepts LLC bought a new stake in BioNTech in the 2nd quarter valued at $39,000. Caitong International Asset Management Co. Ltd increased its position in BioNTech by 1,012.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock worth $53,000 after buying an additional 506 shares during the period. Vestcor Inc acquired a new stake in shares of BioNTech during the fourth quarter worth $153,000. Rockefeller Capital Management L.P. lifted its holdings in shares of BioNTech by 328.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock worth $177,000 after buying an additional 1,423 shares in the last quarter. Finally, Quantum Portfolio Management LLC bought a new stake in shares of BioNTech in the first quarter valued at about $203,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Trading Up 0.8%

Shares of BioNTech stock opened at $97.64 on Friday. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The stock has a market cap of $24.69 billion, a P/E ratio of -12.47 and a beta of 1.25. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $98.94 and its 200-day moving average is $95.06.

BioNTech (NASDAQ:BNTX – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The company had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company’s quarterly revenue was down 59.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.60) EPS. Equities research analysts predict that BioNTech will post -6.37 earnings per share for the current fiscal year.

About BioNTech

(Get Free Report)

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.

Further Reading